Posted by Michael Wonder on 18 May 2023
FDA approves first oral treatment for moderately to severely active Crohn’s disease
18 May 2023 - The FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumour necrosis factor blockers.
Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease.
